MedPath

Lymphocyte to Procalcitonin Ratio in Covid-19 Patients

Active, not recruiting
Conditions
COVID-19
Registration Number
NCT06620159
Lead Sponsor
Suleyman Demirel University
Brief Summary

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age.

Detailed Description

The lymphocyte/CRP ratio has been studied many times in covid-19 patients and has been proven to be an indicator of mortality as well as poor prognosis. In this study, the role of the lymphocyte/procalcitonin ratio in predicting the hospitalization status of patients, detection of findings on CT, need for mechanical ventilation, mortality and survival is aimed to be determined. The lymphocyte/procalcitonin ratio was found to be the strongest predictor of mortality and poor prognosis, especially in patients over 65 years of age. The auc value, PPV and specificity of the lymphocyte/procalcitonin ratio were higher than the lymphocyte/CRP ratio.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
535
Inclusion Criteria
  • Covid19 PCR test positive
Exclusion Criteria
  • Pregnancy Under 18 years old

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
outcome30 days

The relationship between lymphocyte/procalcitonin ratio and 30-day mortality was analyzed.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Süleyman demirel üniversitesi tıp fakültesi

🇹🇷

Isparta, Turkey

© Copyright 2025. All Rights Reserved by MedPath